The existing clinical data on sivelestat use is conflicting, the STRIVE study which enrolled a large, heterogeneous population of mechanically ventilated patients with ARDS, was stopped early on the recommendation of an external Data and Safety Monitoring Board, which noted a negative trend in long-term 180-day mortality rate [ 15 ].
← all excerpts
Neutrophil elastase inhibitor (Sivelestat) in the treatment of acute respiratory distress syndrome induced by COVID-19: a multicenter retrospective cohort study.
1
—
—